Statements (95)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:acquisition |
gptkb:Cephalon
gptkb:Actavis_Generics gptkb:Ratiopharm Allergan's generics business Allergan's generics business (2016) Actavis (2016) Barr Pharmaceuticals (2008) Cephalon (2011) Mylan (proposed, 2020) Ratiopharm (2010) Zydus Cadila (2019) Merck KGa A's generics business (2016) |
| gptkbp:advertising |
gptkb:Dr._Richard_D._Smith
|
| gptkbp:categories |
metabolic disorders
neurology oncology autoimmune diseases central nervous system disorders infectious diseases pain management women's health cardiovascular respiratory |
| gptkbp:ceo |
gptkb:Kåre_Schultz
|
| gptkbp:clinical_trial |
ongoing
conducts numerous clinical trials annually |
| gptkbp:conducts_research_on |
gptkb:Dr._Michael_Hayden
|
| gptkbp:divisions |
gptkb:Teva_Pharmaceuticals_USA
gptkb:Teva_Europe gptkb:Teva_Specialty_Pharmaceuticals Teva API Teva Global Operations |
| gptkbp:employees |
over 40,000
|
| gptkbp:financial_performance |
market fluctuations
research funding investor relations cost reduction initiatives publicly traded dividend policy shareholder value debt management capital expenditures market capitalization stock price volatility profit margins earnings reports stock buybacks analyst ratings guidance updates revenue growth strategies |
| gptkbp:founded |
1901
|
| gptkbp:founder |
gptkb:Eli_Hurvitz
Salomon, Levin, and R. A. M. Teva |
| gptkbp:generic_drug_market_share |
over 20% in the US
|
| gptkbp:global_presence |
over 60 countries
|
| gptkbp:head_of_state |
Richard Francis
|
| gptkbp:headcount |
approximately 38,000 (2021)
|
| gptkbp:headquarters |
Petah Tikva, Israel
|
| https://www.w3.org/2000/01/rdf-schema#label |
Teva
|
| gptkbp:industry |
gptkb:pharmaceuticals
|
| gptkbp:invention |
numerous pharmaceutical patents
holds numerous patents for generic drugs |
| gptkbp:market |
global
|
| gptkbp:market_cap |
$10.5 billion (2021)
|
| gptkbp:market_share |
significant in generics
|
| gptkbp:operates_in |
over 60 countries
|
| gptkbp:partnership |
gptkb:Procter_&_Gamble
gptkb:Astra_Zeneca gptkb:Sanofi gptkb:Boehringer_Ingelheim gptkb:Bristol-Myers_Squibb gptkb:Pfizer |
| gptkbp:partnerships |
various biotech companies
|
| gptkbp:products |
generic drugs
specialty medicines |
| gptkbp:research_and_development |
biopharmaceuticals
focus on oncology focus on CNS disorders focus on respiratory diseases |
| gptkbp:revenue |
$16.7 billion (2020)
|
| gptkbp:social_responsibility |
gptkb:healthcare_access
community engagement education initiatives ethical business practices environmental sustainability |
| gptkbp:stock_exchange |
gptkb:NYSE
|
| gptkbp:stock_symbol |
gptkb:TEVA
|
| gptkbp:subsidiaries |
gptkb:Teva_Pharmaceuticals_USA
gptkb:Actavis |
| gptkbp:sustainability_initiatives |
social responsibility
environmental responsibility economic responsibility |
| gptkbp:bfsParent |
gptkb:Michael_Jordan
|
| gptkbp:bfsLayer |
3
|